Safety Considerations with Omega-3 Fatty Acid Therapy

Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA.
The American Journal of Cardiology (Impact Factor: 3.28). 04/2007; 99(6A):35C-43C. DOI: 10.1016/j.amjcard.2006.11.020
Source: PubMed


It has been suggested that the potential antithrombotic effect of fish oils may theoretically increase the risk for bleeding, which may be a safety concern for individual patients. However, clinical trial evidence has not supported increased bleeding with omega-3 fatty acid intake, even when combined with other agents that might also increase bleeding (such as aspirin and warfarin). Another potential safety concern is the susceptibility of omega-3 fatty acid preparations to undergo oxidation, which contributes to patient intolerance and potential toxicity. Finally, large amounts of fish consumption may result in adverse experiences due to the potential presence of environmental toxins such as mercury, polychlorinated biphenyls, dioxins, and other contaminants. The risks of exposure to environmental toxins and hypervitaminosis with fish consumption are substantially reduced through purification processes used to develop selected concentrated fish oil supplements and prescription preparations. Thus, in choosing which fish oil therapies to recommend, clinicians should be aware of available information to best assess their relative safety, which includes the US Food and Drug Administration (FDA) and Environmental Protection Agency (EPA) advisory statement regarding fish consumption, the meaning of certain labeling (such as "verification" through the US Pharmacopeia) and the differences in FDA regulatory requirements between nonprescription fish oil supplements and prescription fish oil preparations, and how all of this is important to the optimal treatment of patients.

Full-text preview

Available from:
  • Source
    • "studies suggest that α -linolenic acid (a substance found in flaxseed and flaxseed oil) may benefit people with heart disease (Bays 2007; Hou et al., 2007; Ye et al., 2006). The antibacterial test on Bacillus cereus (B. "

    AFRICAN JOURNAL OF BIOTECHNOLOGY 04/2014; 13(18):1915-1919. DOI:10.5897/AJB2014.13732 · 0.57 Impact Factor
  • Source
    • "n-3-LC-PUFAs are highly bioactive compounds, commonly derived from dietary fish oil, and have anti-inflammatory effects at optimal doses (12). n-3-LC-PUFAs have anti-thrombotic effects (16) and contribute to reduced platelet coagulation (17). Accordingly, some animal studies demonstrate that n-3-LC-PUFAs increase bleeding after experimentally induced intracerebral hemorrhage (18). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ischemic stroke is associated with motor impairment and increased incidence of affective disorders such as anxiety/clinical depression. In non-stroke populations, successful management of such disorders and symptoms has been reported following diet supplementation with long chain omega-3-polyunsaturated-fatty-acids (PUFAs). However, the potential protective effects of PUFA supplementation on affective behaviors after experimentally induced stroke and sham surgery have not been examined previously. This study investigated the behavioral effects of PUFA supplementation over a 6-week period following either middle cerebral artery occlusion or sham surgery in the hooded-Wistar rat. The PUFA diet supplied during the acclimation period prior to surgery was found to be associated with an increased risk of acute hemorrhage following the reperfusion component of the surgery. In surviving animals, PUFA supplementation did not influence infarct size as determined 6weeks after surgery, but did decrease omega-6-fatty-acid levels, moderate sickness behaviors, acute motor impairment, and longer-term locomotor hyperactivity and depression/anxiety-like behavior.
    Frontiers in Neurology 02/2014; 5(14):1. DOI:10.3389/fneur.2014.00014
  • Source
    • "Additionally, the intake of ω-3 PUFAs is helpful in the prevention of cardiovascular disease [26]. Hence, the beneficial effects of ω-3 PUFAs on the treatment of hyperlipidemia have been extensively studied in both humans [27] and animals [28], [29], showing a potent hypolipidemic effect. Regarding the mechanism of action of both proanthocyanidins and ω-3 PUFAs, the evidence has recently shown that these dietary compounds can modulate miRNAs expression. "
    [Show abstract] [Hide abstract]
    ABSTRACT: miR-33 and miR-122 are major regulators of lipid metabolism in the liver, and their deregulation has been linked to the development of metabolic diseases such as obesity and metabolic syndrome. However, the biological importance of these miRNAs has been defined using genetic models. The aim of this study was to evaluate whether the levels of miR-122 and miR-33a in rat liver correlate with lipemia in nutritional models. For this purpose, we analyzed the levels of miRNA-33a and miR-122 in the livers of dyslipidemic cafeteria diet-fed rats and of cafeteria diet-fed rats supplemented with proanthocyanidins and/or ω-3 PUFAs because these two dietary components are well-known to counteract dyslipidemia. The results showed that the dyslipidemia induced in rats that were fed a cafeteria diet resulted in the upregulation of miR-33a and miR-122 in the liver, whereas the presence of proanthocyanidins and/or ω-3 PUFAs counteracted the increase of these two miRNAs. However, srebp2, the host gene of miR-33a, was significantly repressed by ω-3 PUFAs but not by proanthocyanidins. Liver mRNA levels of the miR-122 and miR-33a target genes, fas and pparβ/δ, cpt1a and abca1, respectively, were consistent with the expression of these two miRNAs under each condition. Moreover, the miR-33a and abca1 levels were also analyzed in PBMCs. Interestingly, the miR-33a levels evaluated in PBMCs under each condition were similar to the liver levels but enhanced. This demonstrates that miR-33a is expressed in PBMCs and that these cells can be used as a non-invasive way to reflect the expression of this miRNA in the liver. These findings cast new light on the regulation of miR-33a and miR-122 in a dyslipidemic model of obese rats and the way these miRNAs are modulated by dietary components in the liver and in PBMCs.
    PLoS ONE 07/2013; 8(7):e69817. DOI:10.1371/journal.pone.0069817 · 3.23 Impact Factor
Show more